Sector News

Kiss more pharma jobs goodbye: Pierre Fabre to cut 550 in sales, R&D

December 11, 2014
Life sciences
Pierre Fabre hasn’t had an easy time in the drug business lately. Its R&D operations have been less than productive, executives say, and sales in its home country have suffered from price cuts.
 
So, it’s scaling back in pharma to narrow its R&D focus, build up in consumer healthcare and spend more resources on its cosmetics and dermatology businesses. The upshot? Pierre Fabre will shrink its pharma payroll by 551 jobs by 2016. The cuts will mainly affect its French operations, with sales and R&D both in the target zone.
 
The larger cuts will come in R&D, which will lose 272 jobs, 255 in France, the company said in a statement. Another 279 or so will hit on the sales side. The rest will come from an R&D site in Barcelona that’s slated for closure.
 
The job cuts aren’t likely to be popular in France, where Sanofi ran into trouble with its own restructuring. Nor are the company’s comments about its R&D operations in the country, which it called “insufficiently productive.” That, too, echoes Sanofi, whose now-former CEO Chris Viehbacher cited the same reason for his French job-cutting plans in R&D.
 
Pierre Fabre is far from the only drugmaker cutting jobs and paring away lackluster businesses–not to mention scaling back in France. Novartis just cut 200 people from its New Jersey payroll in a sales-force shift, and it’s cutting other jobs around the world as it consolidates back-office operations. The Swiss drugmaker is also in the midst of a wholesale strategic shift, selling its animal health business to Eli Lilly and swapping its vaccine business to GlaxoSmithKline for GSK’s oncology operations. GSK announced job cuts last week as well.
 
Bristol-Myers Squibb also said last week it would hack 1,000 from its Chinese payroll. And Merck is cutting costs–as well as jobs–as it narrows its focus; the U.S.-based drugmaker recently sold its consumer business to Bayer.
 
By Tracy Staton
 

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach